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Leachatesa b s t r a c t
To study the impact of different semi-solid dosage form components on the leaching of Bisphenol A (BPA)
and Bisphenol A diglycidyl ether (BADGE) from the epoxy resin-based inner lacquer of aluminium tubes,
the tubes were filled with different matrix preparations and stored at an elevated temperature. Despite
compliance with the European Standards EN 15348 and EN 15766 on porosity and polymerisation of inter-
nal coatings of aluminium tubes, the commercially available tubes used in the study contained an increased
amount of polymerisation residues, such as unbound BPA, BADGE and BADGE derivatives in the lacquer, as
determined by acetonitrile extraction. Storage of Macrogol ointments in these tubes resulted in an almost
quantitativemigration of the unboundpolymerisation residues from the coating into the ointment. In addi-
tion, due to alterations observed in the RP-HPLC chromatograms of the matrix spiked with BADGE and
BADGE derivatives it is supposed that the leachates can react with formulation components.
The contamination of the medicinal product by BPA, BADGE and BADGE derivatives can be precluded by
using aluminium tubes with an internal lacquer with a low degree of unbound polymerisation residues.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Aluminium tubes are commonly used as container closure sys-
tem for medicinal products of semi-solid dosage forms. The tubes
are internally coated to avoid direct contact between the medicinal
products and the metal. The protective coatings usually consist of
Bisphenol A diglycidyl ether (BADGE)-based epoxy resins. These
resins are known for their good mechanical properties and their
chemical resistance [1].
BADGE resin is made from Bisphenol A (BPA) and epichlorohy-
drin. The polymerisation takes place under distinct curing condi-
tions and in the presence of various additional reactants
(hardeners, cross linkers, chain-stoppers, etc.) [2]. Simal-Gándara
et al. [2] discussed the impact of the curing conditions on the
degree of cross-linking and finally on a potential migration of
unreacted compounds. For cans that are coated with
BADGE-based epoxy resins and intended to be used to containfood, a specific migration limit for the sum of BADGE and deriva-
tives (BADGEH2O, BADGE2H2O, BADGEHCl, BADGE 2HCl and
BADGEHClH2O) has been established by the European Commis-
sion [3]. The structures and reactions leading to these derivatives
are outlined by Haverkamp et al. [4].
Previous studies have demonstrated that BADGE and its deriva-
tives, as well as BPA, can also migrate into semi-solid topical
formulations when they are stored in aluminium tubes coated with
epoxy resins [4,5]. Extraction tests, by filling acetonitrile into
empty aluminium tubes and storing them at 40 C for 10 days,
turned out to be a suitable method to estimate the amount of unre-
acted BPA and BADGE in the coating [4]. A plain variability was
found in the extraction profiles among commercially available
tubes from different vendors. Among them, one type of tubes (tube
A, vendor A) resulted in the highest extractable amount of BPA,
BADGE and BADGE derivatives. This was confirmed for two differ-
ent lots of this tube type [4].
The migration of leachables from the coating into topical medic-
inal products of semi-solid dosage forms was examined by using
appropriate migration studies [4,5]. In addition to the expected
correlation between migration and storage temperature or dura-
tion, a distinct effect of the matrix on the extent of migration
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polarity turned out to play a crucial role [4].
There is a wide variety of semi-solid medicinal products; some
of them are single-phase systems, and others are multiple-phase
systems. Often, emulsifying agents are used to stabilise emulsions
of water and oil phases and to enhance dispersion/solubility of an
active ingredient. Such medicinal products may also contain addi-
tional excipients, such as antioxidants, preservatives and/or excip-
ients that can help to optimise the topical drug release rate, drug
stability, and local tolerance [6]. The aim of the study was to eval-
uate the impact of certain matrix components on the migration of
BADGE derivatives from the inside-coating of aluminium tubes
into semi-solid medicinal products.
The European Committee for Standardisation (CEN) published
two technical documents with test methods for evaluating the
quality of internal lacquer of flexible aluminium tubes [7,8]. While
EN 15384 describes a method to evaluate the porosity of the lac-
quer, EN 15766 provides a standard procedure for determining
the polymerisation of the internal coating of the tubes. The validity
of these tests for identifying aluminium tubes with a high amount
of unreacted BADGE and BPA as polymerisation residues in the
internal coating was also evaluated during this study.2. Materials
2.1. Reference substances
Reference substances used for these studies were described by
Haverkamp et al. [4]. The internal standard Bisphenol A di-3-
hydroxypropylether (BADHPE), CAS No. [37353-75-6] was purified
as described in [4].2.2. Chemicals
Acetonitrile was HPLC gradient grade (Sigma–Aldrich, Stein-
heim, Germany). Unless otherwise mentioned, further reagents
were of analytical grade. n-Heptane and methanol were obtained
from Sigma–Aldrich (Steinheim, Germany). Ammonium formate,
and formic acid were purchased from Fluka (Buchs, Switzerland),
and acetic acid, acetone, sodium hydroxide and sodium sulphate
anhydrous from Merck (Darmstadt, Germany). Sorbitan monos-
tearate (SpanTM 60) was bought from Sigma–Aldrich (St. Louis,
MO, USA), and polyoxyethylene (20) sorbitan monostearate
(polysorbate 60, TweenTM 60) from Caesar & Loretz, Germany.
Water was obtained from a Milli-Q water purification system
(Millipore, Molsheim, France). Solid phase extraction was carried
out on Bakerbond C18 500 mg/3 mL columns (Mallinckrodt Baker,
Deventer, The Netherlands). Polyethylene glycols (Macrogol) and
all further matrix ingredients were of Ph. Eur. grade and purchased
from Caelo (Hilden, Germany).2.3. Aluminium tubes
Two kinds of tubes for pharmaceutical use (type A and type M)
were purchased from two different vendors. For type A, 5 mL tubes
of two batches (type A#1, type A#2) were used. Tubes of type M
had a nominal volume of 10 mL. All tubes were internally lac-
quered with BADGE based epoxy resins (verified via AT-FTIR, data
not shown).2.4. Matrices
1.5 kg of each matrix was custom-made in a Unimix (Haagen &
Rinau Mischtechnik, Bremen, Germany). Einfache Augensalbe DAC(Eye Ointment) and Macrogolsalbe DAC (Macrogol Ointment) were
prepared according to [9].
For preparation of Eye Ointment white soft paraffin (60% w/w)
and liquid paraffin (40% w/w) were stirred with 20 rpmwhile heat-
ing to approx. 70 C until white soft paraffin was visually dissolved.
The Eye Ointment was further modified by addition of either
polysorbate 60 or sorbitan monostearate to a nominal concentra-
tion of 10% emulsifier related to the amount of original Eye Oint-
ment (final concentration 9.1% w/w). For preparation of Macrogol
Ointment the polyethylene glycols 300 and 1500 (both 50% w/w)
were heated to approx. 40 C and stirred with 20 rpm as well.
Once having reached visual homogeneity, heating was deacti-
vated and all aforementioned matrices were stirred overnight.
Equally, 1 kg of a Macrogol/cetyl alcohol matrix was prepared
containing Macrogol 400 (75.8%), Macrogol 1500 (4.1%), Macrogol
4000 (8.2%), cetyl alcohol (11.4%) and 0.5 M sodium acetate buffer
pH 4.0 (0.5%).2.5. Apparatus/HPLC methods
Leachables and extractables were analysed by use of RP-HPLC
analysis (Dionex, Germering, Germany) using a binary gradient
elution with 5 mM ammonium formate buffer and a methanol/ace-
tonitrile (2:1) mixture coupled with fluorescence detection
(kEX = 275 nm; kEM = 305 nm) as described by Haverkamp et al.
[4] except for the Macrogol/cetyl alcohol matrix. Here, a slightly
modified method was applied with an altered gradient containing
methanol only starting isocratically with 60% methanol up to
15 min followed by a linear increase to 65% up to 22 min and to
70% up to 34 min. A Multospher 100 RP18-5 l, 250  4 mm column
(CS-Chromatographie, Langerwehe, Germany) was used as station-
ary phase.3. Methods
3.1. Extraction studies
The extraction studies were described by Haverkamp et al. [4].3.2. Migration studies
The migration studies described in [4] were slightly modified to
take into account high amounts of leachates from the aluminium
tubes. Only one lot of tube A was used in one experiment to
exclude effects of batch-to-batch variability.
Tubes of one supplier were manually filled, closed by folding
and stored with closures down in a rack at 30 C (intermediate)
or 40 C (accelerated), according to the current EU regulatory
guideline for stability studies with drug products [10]. For refer-
ence, the matrix samples were simultaneously stored in closed
glass containers at identical temperature conditions and protected
from light. The Macrogol/cetyl alcohol matrix was additionally
stored in glass containers after spiking with BPA, BADGE and its
derivatives (at about 0.8 mg/kg matrix).
Sampling of tubes and blank matrices was done at defined
intervals. Container tightness was checked by means of differential
weighing. Samples of tubes were mechanically stressed once per
week to simulate in-use conditions as described by [4].3.3. Sample preparation for HPLC analysis
After removal of the semi-solid formulae out of the tubes, a
quantitative extraction of the analytes from the matrices was nec-
essary prior to HPLC analysis. For this purpose, the contents of two
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Ointment was prepared as described by [4].3.3.1. Eye Ointment + 10% SpanTM 60
Aliquots of 5.0 g matrix, removed from the tubes, were weighed
in flasks in triplicate and spiked with 1 mL acetonitrile containing
5.0 mg/L internal standard, giving a BADHPE concentration of
1.0 mg/kg. 20 mL n-heptane and 19 mL acetonitrile were added
to the flask, and the matrix was suspended via vigorous shaking.
In the case of incomplete suspension, the sample was sonicated
(Sonorex RK 100 H, Bandelin, Berlin, Germany) for a maximum of
5 min to achieve a visually homogeneous suspension. Liquid–
liquid-extraction was carried out using 2  20 mL acetonitrile, fol-
lowed by freezing of the acetonitrile phase at about 20 C for at
least 2 h. Filtration with folded paper filters (Ø 90 mm, Schleicher
& Schüll Nr. 595 1/2, Dassel, Germany) over sodium sulphate anhy-
drous, followed by rinsing with acetonitrile (2  5 mL) cooled
down to 20 C, removes sufficiently the emulsifier, which would
hinder the subsequent evaporation by foaming.
The combined acetonitrile fractions were evaporated to dryness
(40 C) under vacuum and further treated as described for Eye Oint-
ment in [4].3.3.2. Eye Ointment + 10% polysorbate 60
Aliquots of 5.0 g matrix were weighed in flasks in triplicate and
spiked with 2 mL acetonitrile containing 50.0 mg/L internal stan-
dard, giving a BADHPE concentration of 20.0 mg/kg. 20 mL n-
heptane and 18 mL acetonitrile were added to the flask, and the
matrix was suspended as described above. Further sample prepa-
ration was carried out as described under Eye Ointment in [4],
except following the SPE treatment. Here, the combined eluates
from the SPE were transferred into a 20 mL volumetric flask,
4.2 mL acetonitrile was added, and the flask was filled up with
water (HPLC quality). The injection volume was 10 lL and 100 lL
in order to fit the validated working range.3.3.3. Macrogol Ointment
Aliquots of 2.5 g matrix were weighed in flasks in triplicate and
spiked with 2 mL acetonitrile containing 50.0 mg/L BADHPE, giving
a concentration of 40.0 mg/kg.
6.4 mL of acetonitrile was added to the flask and the matrix was
dissolved by manual shaking. The solution was transferred into
20 mL volumetric flasks and brought up to volume with water.
After filtration through 0.45 lm filters (Chromatfil PET 45/15 MS,
Machery-Nagel, Düren, Germany), quantitation took place by
injecting 10 lL and 100 lL in order to fit the validated working
range.3.3.4. Macrogol/cetyl alcohol matrix
Aliquots of 2.5 g matrix were weighed in flasks in triplicate and
spiked with 40 lL of acetonitrile containing 50.0 mg/L BADHPE,
giving a concentration of 0.8 mg/kg.
20 mL of acetonitrile was added to the flask and the matrix was
suspended by vigorous shaking and by an ultrasound bath (see
above in Section 3.3.1 for details). The suspension was stored at
20 C overnight and then filtrated with folded paper filters
(Ø 90 mm, Schleicher & Schüll Nr. 595 1/2, Dassel, Germany),
followed by rinsing with frozen (20 C) acetonitrile (2  5 mL)
in order to remove as much cetyl alcohol as possible. The combined
acetonitrile fractions were evaporated to dryness (40 C) under
vacuum. The residue was transferred, with 6 mL of acetonitrile,
in small portions, into a 20 mL volumetric flask and brought to
volume with water.3.4. Method validation
Analytical method validation was performed with the modified
Eye Ointments and the Macrogol Ointment as described in [4]. The
limit of detection (LOD) and the limit of quantification (LOQ) were
determined separately for each matrix, based on recovery data in
accordance with DIN 32645 [11]. For the qualitative investigations
with the Macrogol/cetyl alcohol matrix, specificity/selectivity and
LOD were tested in line with ICH Q 2 (R1) [12].
3.5. Test on porosity and polymerisation of internal lacquer
The tests were performed according to EN 15384 [8] and EN
15766 [7]. According to EN 15766, the coating was swabbed using
cotton saturated with acetone. The cotton was inspected for
colouration and the coating for fading or discolouration.4. Results and discussion
4.1. Method validation
The quantification method for BADGE and its derivatives,
including the preparation procedure of the semi-solid matrices,
has already been successfully validated for selected ointments,
creams and gels [4]. Linearity has been confirmed for the working
range between the limit of quantitation (LOQ) and 500 lg/L of the
analytes as BADGE, BADGE derivatives and BPA.
In order to verify the validation results and to exclude any inter-
ference of the method by the components of the matrices, the
recovery of the analytes in Eye Ointment modified matrices and
in Macrogol Ointment was also evaluated (Table 1). The results for
precision, recovery as well as LOD and LOQ were slightly higher
than determined in the matrices previously tested [4]. Nonethe-
less, the validation data, presented in Table 1, confirm the suitabil-
ity of the preparation scheme to quantify BPA, BADGE and its
derivatives in the selected matrices.
4.2. Physicochemical characterisation of the tubes
For the purpose of evaluating differences in the physicochemi-
cal characteristics of the inner lacquer of the two tubes, the poros-
ity and polymerisation of tube A and tube M were tested in
accordance with the EN Standards 15766 and 15384 [7,8]. The test
results showed no differences, neither between the different lots of
tube A (test on porosity and polymerisation) nor between tube A
and tube M (test on polymerisation) (Table 2). All tubes fulfilled
the requirements of EN 15766 and EN 15384.
However, relevant differences in the amount of polymerisation
residues BADGE, BADGE derivatives, and BPA in the coatings
became obvious when extracting the tubes by use of acetonitrile
(Table 2). A significantly lower level of all extractables was found
in tube M. Particularly, the level of extractable BADGE was deter-
mined to be more than 100 times lower in tube type M than in tube
A. In addition, a clearly smaller amount of the BADGE derivatives
studied was measured, as well as of BPA. These differences cannot
be attributed to the smaller volume of tube A in relation to tube M.
As indicated in Table 2, the ratio between wetted area and volume
does not significantly differ between tube A and tube M. Instead,
differences in the epoxy resin curing process are assumed to be
responsible for this considerably different amount of extractables.
Difference in the amounts of extractables BADGE, BADGE
derivatives and BPA was also detected among two batches of tube
A (Table 2). Haverkamp et al. [4] discussed the curing process as
the most likely cause for this difference. The certificates of analysis
supplied by the tube vendor were related to the lacquer in general
Table 1
Exemplary validation data of the matrices spiked with 20, 100, 200 lg/kg (modified Eye Ointments, mean of n = 3 each) and 40, 200, 400 lg/kg (Macrogol Ointment, mean of n = 3
each).
Validation parameter Compound
BADGE2H2O BPA BADGEH2O BADGEHClH2O BADGE BADGEHCl BADGE2HCl
Eye Ointment + SpanTM 60
LOD/LOQ 7.4/26 7.4/26.1 4.8/17.1 4.6/16.3 4.0/14.4 10.3/35.7 (⁄) 18.1/61.7 (⁄)
Recovery 117.2/105.3/106.2 116.7/111.4/115.6 97.0/101.5/101.3 107.8/98.6/98.0 94.9/91.2/88.7 85.5/86.3/84.7 60.2/83.7/89.6
Precision 4.9/2.2/1.9 9.8/5.8/1.9 9.0/5.1/1.5 7.0/1.5/2.5 5.4/2.4/2.2 10.4/4.7/2.5 14.0/9.0/2.5
Eye Ointment + Polysorbate 60
LOD/LOQ 8.6/30.7 3.1/10.7 2.8/9.5 2.8/9.9 2.7/9.2 2.8/9.7 3.8/13.3
Recovery 102.8/104.3/102.8 100.0/102.1/103.0 96.8/100.1/100.4 95.6/100.7/100.5 94.9/101.4/103.0 93.7/102.8/102.9 98.2/101.5/102.0
Precision 9.9/2.7/1.8 0.6/0.5/0.3 0.9/0.6/0.3 1.3/<0.1/0.2 0.3/0.2/0.3 1.3/0.4/0.2 1.3/0.5/0.4
Macrogol Ointment DAC
LOD/LOQ 10.3/36.6 6.7/24.2 14.9/52.4 9.3/33.1 5.0/18.1 5.6/20.0 7.4/26.6
Recovery 106.6/99.3/101.3 108.4/100.4/102.5 119.9/101.4/102.3 113.2/100.0/101.5 99.9/98.4/100.9 102.2/98.3/101.8 104.6/98.3/101.0
Precision 4.4/1.4/2.8 1.8/0.8/0.7 10.3/4.8/1.6 5.4/0.7/1.0 3.1/0.4/1.0 2.8/0.8/0.9 7.0/1.2/0.4
Recoveries at the different concentrations and precision (RSD) are given in percentage. Limits of detection (LOD) and limits of quantitation (LOQ), given in lg/kg, were
calculated according to DIN 32645 [11]. Due to the absence of relevant peaks during migration study heteroscedasticity of labelled analytes (⁄) was ignored.
Table 2
Physical properties and extraction study results of aluminium tube M in comparison with tube A.
Tube A Tube M
Batch A#1 Batch A#2
Dimension Size 5 mL 5 mL 10 g (approx. 10 mL)a
Wetted area during extraction (dm2)b 0.1645 0.1645 0.2739
Size/wetted area (mL/dm2) 30.4 30.4 36.5
Physical tests Test on polymerisation (EN 15766) Complies Complies Complies
Test on porosity (EN 15384) Complies Complies Not tested
Extractables by acetonitrile extraction (mg/6 dm2)c BADGE2H2O 0.063 ± 0.007d 0.031 ± 0.006d 0.011 ± 0.002
BPA 0.136 ± 0.017d 0.174 ± 0.019d 0.067 ± 0.004
BADGEH2O 1.142 ± 0.111d 0.771 ± 0.042d 0.028 ± 0.009
BADGEH2OHCl 0.010 ± 0.002d 0.010 ± 0.001d n.d.
BADGE 10.468 ± 0.857d 5.635 ± 0.365d 0.032 ± 0.014
BADGEHCl 0.288 ± 0.024d 0.233 ± 0.015d n.d.
BADGE2HCl n.d.d n.d.d n.d.
R extractables BADGE, BADGEH2O, and BADGE2H2O, calculated as BADGE (mg/6 dm2) 11.609 ± 0.864 6.396 ± 0.367 0.069 ± 0.016
n.d.: not detectable.
a Calculated based on the area wetted during extraction.
b Calculated for a cylindric column, wetted at bottom and coat.
c Mean ± standard deviations (n = 5), units in accordance with foodstuff legislation [17].
d Calculated based on data published [4].
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dor A was based on analyses performed by an external laboratory
after curing the lacquer onto suitable inert substrates under labo-
ratory conditions. Thus, the certificates only confirm general suit-
ability of the lacquer for coating purposes but do not reflect the
batch-specific properties resulting from the specific curing process
of the epoxy resin lacquer on the tube.
The impact of curing conditions on the cross-linking degree and
eventually on the amount of polymerisation residues has already
been discussed by Simal-Gándara et al. [2]. They stressed that
residual monomers remain in the epoxy resin inner coating if the
curing parameter in particular for BADGE-based coatings is not
correctly selected. Crucial curing conditions include curing time
and (high) temperature [2]. If these settings are not suitable for
the used equipment or not adequately controlled, the curing pro-
cess may be incomplete. Batch-to-batch variability, variability
within batches as well as higher amounts of residual monomers
could be the consequence.
The study results further indicate that compliance with the
published standards on evaluation of the internal lacquer of alu-
minium tubes does not give assurance that the level of polymerisa-
tion residues in the coating is low. Appropriate extraction studies
of aluminium tubes as described by Haverkamp et al. [4] are indis-pensable for assessing the level of residual monomers in the epoxy
resin lacquer and cannot be replaced by applying the European
Standards EN 15766 and EN 15348 [7,8].
4.3. Formulation-dependent leaching of BADGE and its derivatives
In order to study whether the presence of an emulsifier in the
medicinal product would have an impact on BADGE migration,
typical formulations from German Drug Codex (DAC) were chosen
as a model semi-solid dosage form. To see any difference concern-
ing the influence on migration by hydro-/lipophilic balance we
have selected two similar emulsifiers: the more lipophilic sorbitan
monostearate (SpanTM 60) and the more hydrophilic poly-
oxyethylene (20) sorbitan monostearate (polysorbate 60, TweenTM
60).
Both emulsifiers are well-described by pharmacopeia mono-
graphs and were alternatively added to the Eye Ointment formula-
tion at a final concentration of approximately 10%. Chemical
structures of the two emulsifiers are shown in Table 3. The spiked
ointments were filled into aluminium tube A and stored up to
26 weeks at 40 C.
Eye Ointment spiked with SpanTM 60 did not show a significantly
different leaching profile when compared with the results reported
Table 3
Emulsifiers Polysorbate 60 (TweenTM 60) and SpanTM 60.
Polysorbate 60 (Tween 60TM) Span 60TM
Chemical name Polyoxyethylene sorbitan monostearate Sorbitan monostearate
Structure
HLB 14.9 4.7
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not shown). Similar to the Eye Ointment, predominantly BADGE
migrated into the modified matrix at a comparable low level
(approximately 24 lg/kg) after 6 months of storage.
However, the presence of polysorbate 60 (TweenTM 60) in Eye
Ointment DAC resulted in a considerable increase in the total
amount of leachates in the ointment (Fig. 1). Already after two
months of storage the amount of BADGE was more than 250 fold
higher than in the unmodified ointment. Except for BADGE2HCl,
all BADGE derivatives, including BADGE2H2O, BADGEH2O,
BADGEHClH2O, and BADGEHCl as well as BPA, could be detected
in the ointment spiked with polysorbate 60. BADGE was the
predominant leachate, followed by BADGEH2O, which is formed
after migration of BADGE by partial hydrolysis due to water
present in the matrix [4]. According to the corresponding certifi-
cate of analysis, polysorbate 60 contained about 2.5% of water.Fig. 1. Amount of BPA, BADGE and BADGE derivatives in Eye Ointment spiked with
emulsifiers and inMacrogol Ointment DAC after storage in tube type A at 40 C. Error
bars reflect one standard deviation (n = 3).A total sum of 15 mg/kg of all derivatives including BPA (calcu-
lated as BADGE), was quantified after 6 months of storage at the
chosen storage conditions. As demonstrated in Fig. 1, leaching of
BADGE derivatives from tube A into Eye Ointment spiked with
polysorbate was nearly completed at the first sampling and testing
point, i.e. after eight weeks of storage. The total amount of
migrated substances did not significantly increase over the next
four months of storage.
The results demonstrate that the presence of an emulsifier
alone does not trigger the release of polymerisation residues from
the coating. Thus, differences in the molecular structure of polysor-
bate 60 (TweenTM 60) and sorbitan monostearate (SpanTM 60) were
assumed to induce leaching. Beside the HLB-values (Table 3), the
main difference between the two emulsifiers is the occurrence of
oxyethylene units in polysorbate 60. In order to verify whether
oxyethylene moieties in the matrix trigger leaching of BPA, BADGE
and its derivatives, Macrogol Ointment DAC, a mixture of polyethy-
lene glycol 300 and 1500 in a ratio of 1:1 (w/w), was filled into
tubes of type A.
Fig. 1 shows that already after one week of storage at 40 C, the
amount of the polymerisation residues in the Macrogol Ointment
was considerably higher than in the Eye Ointment DAC spiked with
polysorbate 60, resulting in an overall amount of approximately
28 mg of BADGE per kg Macrogol Ointment. No relevant increase
could be observed during the following weeks, thus demonstrating
that the migration of BADGE and BADGE derivatives into the
polyethylene glycol matrix had already reached equilibrium after
storage at 40 C for one week only. Hydrolysed BADGE derivatives
and BPA were also present in the matrix (Fig. 1). In contrast to the
overall amount of leachates, the amount of the hydrolysed
derivatives further increased during storage, presumably due to
hydrolysis of BADGE in the matrix, whereas the percentage of
non-hydrolysed BADGE simultaneously decreased [4]. Further-
more, BADGEHCl and BADGEHClH2O, but not BADGE2HCl, were
detectable in relevant concentrations.
The relation between the amount of polymerisation residues
determined in tubes of type A by extraction studies with acetoni-
trile, and their amounts measured in the semi-solid products after
storage, is demonstrated in Fig. 2. While addition of the emulsifier
SpanTM 60 did not increase leaching of polymerisation residues into
the matrix, the presence of ethylene glycol moieties in polysorbate
60 considerably promoted the migration of BADGE and BADGE
derivatives from the epoxy resin into the product. Up to 30% of
the total extractable amount was determined after storage at
40 C for two months (Fig. 2). A total amount of more than 90%
was observed with Macrogol Ointment stored at 40 C. But even
when stored at 30 C, a recommended storage temperature for
long-term stability studies in compliance with ICH [10] up to
60% of the potential maximum amount of leachables was
determined in the ointment when stored in tube A (Fig. 2).
Neither BADGE nor BADGE derivatives could be quantified in
the ointment after storage at 40 C for 8 weeks when Macrogol
Ointment was stored in aluminium tube M (Table 4). All analytes
(BADGE and BADGE derivatives) remained significantly below
LOQ. Solely, BPA leached into the matrix. In-use conditions, by
Fig. 2. Sum of leachates from tube A#2 after two months of storage at 40 C, if not indicated otherwise, in relation to the sum of extractables determined by extraction with
acetonitrile (7 days, 40 C) set as 100%. ⁄stored in tube A#1.
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resulted in a slight increase of up to 130 lg BPA per kg Macrogol
Ointment, which was still four times lower than with tube A (data
not shown).
Oxyethylene-like structures within a semi-solid medicinal
product appear to have extractive properties resulting in a nearly
quantitative release of the polymerisation residues from the inner
lacquer of aluminium tubes. This already leads to a considerably
high level of leachates in the medicinal product after only a
short time of contact at recommended storage temperature.
Contamination of a semi-solid product containing components
with oxyethylene structures can be precluded when aluminium
tubes are used with a low level of extractable polymerisation
residues, as in tube M.
4.4. Impact of leachables on product purity
Additionally, a stability study was initiated in order to evaluate
the impact of the aluminium tubes on semi-solid formulation pur-
ity. For this purpose, a Macrogol/cetyl alcohol matrix used in com-
mercially available drug products was prepared and filled in
parallel into tubes of type A and M and in glass containers for ref-
erence. All containers were stored at 30 C. Samples were pulled at
several points of time and analysed using RP-HPLC.
In Fig. 3, the chromatograms of the Macrogol/cetyl alcohol
matrix stored in tube A (line A) and in tube M (line B) are presented
after 19 days of storage. The chromatogram of the matrix stored in
tube A showed a high number of peaks, most of them with
considerable peak areas whereas only a very few minor peaks were
observed with the matrix stored in tube M. Compared to the
chromatogram of a standard solution (containing all studied
compounds; Fig. 3, line C), all peaks could be clearly detected inTable 4
Leachates in Macrogol Ointment stored in aluminium tube type M at 40 C for 8 weeks and
acetonitrile at 40 C for 10 days (⁄⁄data calculated in lg/L from Table 2).
Analytes BADGE 2 H2O BPA BADGE H
Macrogol Ointment by migration (lg/kg matrix)
Day 56 <LOQ 54.2 ± 19.6 <LOQ
In-use <LOQ 127 ± 8 <LOQ
Acetonitrile extraction (lg/L)⁄⁄
50.5 ± 8.4 307 ± 20 126 ± 40
Mean and SD of samples tested (migration study, n = 3; extraction study, n = 5; ⁄n = 2)the chromatogram of the matrix after storage in tube A but not
after storage in tube M. This finding confirms the results described
above for Macrogol ointment.
Besides the peaks concurrent with the standard solution,
numerous additional peaks appeared in the chromatogram of the
matrix from tube A, which were also not seen to the same extent
in the RP-HPLC chromatogram of tube M matrix. These peaks were
not further identified in the frame of this study. Thus, the origin of
these peaks and their identity cannot finally be confirmed. How-
ever, it is assumed that these peaks indicate additional unbound
chemical compounds other than the BPA, BADGE and the BADGE
derivatives studied. This assumption is supported by the extraction
profile of tube A which was obtained by extracting the empty tubes
with acetonitrile [4]. In this chromatogram a large number of addi-
tional peaks beside BPA, BADGE and its derivatives could be
detected. The results with Macrogol/cetyl alcohol matrix stored
in tube A suggest that these multiple extractable compounds are
also capable to migrate from the inner lacquer of tube A into the
ointment. Similar results were also obtained with Macrogol Oint-
ment stored in tube A (data not shown).
Thus, storage of the matrix in tube A does not only result in a
higher contamination of the ointment by BPA, BADGE and BADGE
derivatives but overall in a significant higher amount of chemical
compounds which are not present in the ointment when stored
in tube M.
In view of the reactivity of the epoxy structure of BADGE, how-
ever, at least some of these peaks might also indicate reaction
products of BADGE and formulation components. This hypothesis
is supported by the fact that peak detection was conducted by flu-
orescence measurement (excitation at UV 275 nm and emission at
305 nm), which can be considered selective for molecules with
structures similar to BADGE or BPA. Furthermore, Petersen et al.under simulated in-use conditions compared with the amounts extracted by means of
2O BADGEH2OHCl BADGE BADGEHCl
<LOD <LOQ⁄ <LOD
<LOD <LOQ <LOD
<LOD 148 ± 63 <LOD
Fig. 3. RP-HPLC chromatogram of Macrogol/cetyl alcohol matrix stored in tube A (line A) and in tube M (line B) and BADGE standard solution (line C) for reference. 1,
BADGE2H2O; 2, BPA; 3, BADGEH2O; 4, BADGEH2OHCl; 5, BADGE; 6, BADGEHCl; 7, BADGE2HCl; IS, internal standard (BADPHE); IS⁄, impurity of BADPHE.
Fig. 4. RP-HPLC chromatogram of Macrogol/cetyl alcohol matrix stored in glass vials with (line E) and without (line F) addition of standard solution. The circles indicate the
changes in the spiked matrix within 19 days of storage only. Line D shows the standard solution used for spiking. 1, BADGE2H2O; 2, BPA; 3, BADGEH2O; 4, BADGEH2OHCl; 5,
BADGE; 6, BADGEHCl; 7, BADGE2HCl; IS, internal standard (BADPHE); IS⁄, impurity of BADPHE.
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components after their migration from coated cans used in food
packaging.In order to verify that BADGE and its derivatives can react with
components of the matrix, the Macrogol/cetyl alcohol matrix was
spiked with the standard solution and was stored for 19 days in
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matrix (line F). In the chromatogram of the spiked matrix (line
E), the peaks corresponding to BPA, BADGE and BADGE derivatives
fully comply with the peaks in the chromatogram of the pure stan-
dard solution (Fig. 4, line D) at comparable concentrations. More-
over, additional peaks emerged in the spiked matrix after 19 days
of storage (line E, indicated by circles). These additional peaks sug-
gest that BADGE and reactive BADGE derivatives underwent reac-
tion with components of the Macrogol/cetyl alcohol matrix. This
assumption is also supported by the fact that after 19 days of stor-
age the peak areas of BADGE (peak 3) and BADGE 1 H2O (peak 5)
were reduced in the chromatogram of the spiked ointment. BADGE
and BADGE 1 H2O are BADGE derivatives with at least one free
epoxide group and thus capable to react easily with a second
chemical entity. The peak areas of all other derivatives did not alter
compared to the peaks of the standard solution (line D).
In consequence, storage of semi-solid dosage medicinal prod-
ucts in aluminium tube A with a high level of unbound BADGE
and BPA in the inner lacquer cannot only result in a nearly exhaus-
tive migration of the polymerisation residues from the coating into
the medicinal product but may additionally lead to a contamina-
tion of the product by other unidentified extractable compounds
as well as by reaction products between BADGE and/or reactive
BADGE derivatives with formulation components. This contamina-
tion of the semi-solid formulation by leachables and potential
reaction products impacts the purity of the formulation and thus
has a negative effect on medicinal product quality.
Based on data from an in vitro skin permeation study and from
the literature Søeborg et al. [14] concluded that the immediate
human risk of BADGE and derivatives in topical dosage forms is
low. The Estimated Systemic Exposure Dosage was found signifi-
cantly below the established Total Daily Intake. However, for a
comprehensive risk assessment on BADGE in topical medicinal
product, not only systemic toxicity is to be taken into account,
but also the allergenic potential of BADGE and BADGE derivatives.
Oligomers of BADGE with a mean molecular weight 6700 Da are
the most frequent cause of contact allergy [15]. Recently, it was
demonstrated that BADGE present inMacrogol Ointment in a quan-
tity as determined after storage in tube A can induce allergic skin
reactions when applied by epoxy-resin positive patients [16].
5. Conclusion
The magnitude of leaching predominantly depends on the com-
position of the semi-solid formulation. Components containing
oxyethylene units turned out to have extractive properties, result-
ing in an almost quantitative release of unbound BADGE, BADGE
derivatives and BPA from the inner coating of a tube into the
medicinal product. Polyethylene glycol (PEG) based matrices, such
as Macrogol ointment, are often used as a base for iodine or lido-
caine containing medicinal products for cutaneous application.
Thus, in terms of medicinal product quality and safety, leaching
of BADGE from the coating of the primary packaging into the
medicinal product should be minimised as far as possible. As leach-
ing is affected by formulation components contamination of a
semi-solid medicinal product can only be avoided by using alu-
minium tubes with a low level of non-polymerised BADGE, BPA
and BADGE derivatives. The European Standards EN 15384 and
EN 15766 established for evaluating the porosity and polymerisa-
tion of the internal coating of tubes cannot replace appropriateextraction studies as described by Haverkamp et al. [4]. By means
of these extraction studies aluminium tubes with a low level of
extractables should be selected for medicinal product packaging
in order to ensure the quality of semi-solid medicinal products
up to their end of shelf life.
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